Bioasis Technologies Stock Debt To Equity
| BIOAF Stock | USD 0.0002 0.00 0.00% |
Fundamental analysis of BiOasis Technologies allows traders to better anticipate movements in BiOasis Technologies' stock price by examining its financial health and performance throughout various phases of its business cycle.
BiOasis |
biOasis Technologies Company Debt To Equity Analysis
BiOasis Technologies' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current BiOasis Technologies Debt To Equity | 0.31 % |
Most of BiOasis Technologies' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, biOasis Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, biOasis Technologies has a Debt To Equity of 0.31%. This is 99.42% lower than that of the Biotechnology sector and 98.4% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.36% higher than that of the company.
BiOasis Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiOasis Technologies' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BiOasis Technologies could also be used in its relative valuation, which is a method of valuing BiOasis Technologies by comparing valuation metrics of similar companies.BiOasis Technologies is currently under evaluation in debt to equity category among its peers.
BiOasis Fundamentals
| Return On Asset | -0.81 | |||
| Operating Margin | (11.41) % | |||
| Current Valuation | 6 M | |||
| Shares Outstanding | 79.41 M | |||
| Shares Owned By Insiders | 2.05 % | |||
| Price To Earning | 13.82 X | |||
| Price To Book | 53.47 X | |||
| Price To Sales | 26.52 X | |||
| Revenue | 37.73 K | |||
| Gross Profit | (1.15 M) | |||
| EBITDA | (3.54 M) | |||
| Net Income | (2.96 M) | |||
| Cash And Equivalents | 764.97 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 401.76 K | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 0.38 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (3.64 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 0.58 | |||
| Number Of Employees | 23 | |||
| Beta | 0.39 | |||
| Market Capitalization | 2.13 M | |||
| Total Asset | 2.27 M | |||
| Retained Earnings | (18.69 M) | |||
| Working Capital | 437 K | |||
| Current Asset | 874 K | |||
| Current Liabilities | 437 K | |||
| Z Score | -11.5 | |||
| Net Asset | 2.27 M |
About BiOasis Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze biOasis Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiOasis Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of biOasis Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in BiOasis Pink Sheet
BiOasis Technologies financial ratios help investors to determine whether BiOasis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BiOasis with respect to the benefits of owning BiOasis Technologies security.